Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial

BACKGROUND: Twelve months of oral cyclophosphamide (CYC) has been shown to alter the progression of scleroderma-related interstitial lung disease (SSc-ILD) when compared to placebo. However, toxicity was a concern and without continued treatment the efficacy disappeared by 24 months. We hypothesized...

Descripción completa

Detalles Bibliográficos
Autores principales: Tashkin, Donald P, Roth, Michael D, Clements, Philip J, Furst, Daniel E, Khanna, Dinesh, Kleerup, Eric C, Goldin, Jonathan, Arriola, Edgar, Volkmann, Elizabeth R, Kafaja, Suzanne, Silver, Richard, Steen, Virginia, Strange, Charlie, Wise, Robert, Wigley, Fredrick, Mayes, Maureen, Riley, David J, Hussain, Sabiha, Assassi, Shervin, Hsu, Vivien M, Patel, Bela, Phillips, Kristine, Martinez, Fernando, Golden, Jeffrey, Connolly, M Kari, Varga, John, Dematte, Jane, Hinchcliff, Monique, Fischer, Aryeh, Swigris, Jeffrey, Meehan, Richard, Theodore, Arthur, Simms, Robert, Volkov, Suncica, Schraufnagel, Dean E, Scholand, Mary Beth, Frech, Tracy, Molitor, Jerry A, Highland, Kristin, Read, Charles A, Fritzler, Marvin J, Kim, Grace Hyun J, Tseng, Chi-Hong, Elashoff, Robert M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014629/
https://www.ncbi.nlm.nih.gov/pubmed/27469583
http://dx.doi.org/10.1016/S2213-2600(16)30152-7

Ejemplares similares

Ejemplares similares